Hoechst's Cariporide MI Program Stalls Following Phase III Results
Executive Summary
Hoechst Marion Roussel is debating the future development of its NHE-inhibitor cariporide (HOE 642) for myocardial infarction following results from a Phase III trial that "did not confirm a statistically significant effect of the drug," HMR reported March 2.